Troy A McEachron Ivan Kirov Minkkwan Wungwattana Daisy Cortes Keri B Zabokrtsky Aaron Sassoon David Craig John D Carpten Leonard S Sender
10.1002/pbc.25854
Pediatr Blood Cancer
2016 Apr;63(4):727-30.
stat3 extranodal nk/t-cell lymphoma genome
author_manuscript
https://pubmed.ncbi.nlm.nih.gov/26727971/
Chemoradiotherapy / methods Lymphoma, Extranodal NK-T-Cell / genetics Lymphoma, Extranodal NK-T-Cell / therapy Precision Medicine / methods STAT3 Transcription Factor / genetics
Chemoradiotherapy / methods Lymphoma, Extranodal NK-T-Cell / genetics Lymphoma, Extranodal NK-T-Cell / therapy Precision Medicine / methods STAT3 Transcription Factor / genetics Case Reports Research Support, Non-U.S. Gov't Antineoplastic Combined Chemotherapy Protocols / therapeutic use Asparaginase / administration & dosage Child Cytarabine / administration & dosage DNA Mutational Analysis Dexamethasone / administration & dosage Etoposide / administration & dosage Female Humans Hydrocortisone / administration & dosage Hydroxamic Acids / administration & dosage Ifosfamide / administration & dosage MAP Kinase Kinase 1 / genetics Methotrexate / administration & dosage Mutation Positive Regulatory Domain I-Binding Factor 1 Repressor Proteins / genetics Vorinostat Hydroxamic Acids Repressor Proteins STAT3 Transcription Factor STAT3 protein, human Cytarabine PRDM1 protein, human Vorinostat Etoposide Dexamethasone Positive Regulatory Domain I-Binding Factor 1 MAP Kinase Kinase 1 MAP2K1 protein, human Asparaginase Ifosfamide Hydrocortisone Methotrexate
PMC7510171
26727971
Successful Treatment of Genetically Profiled Pediatric Extranodal NK/T-Cell Lymphoma Targeting Oncogenic STAT3 Mutation
2016